The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global ImmunOthersapy Drugs for Multiple Myeloma Market Research Report 2025
Synopsis
The global ImmunOthersapy Drugs for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for ImmunOthersapy Drugs for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ImmunOthersapy Drugs for Multiple Myeloma.
Report Scope
The ImmunOthersapy Drugs for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ImmunOthersapy Drugs for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ImmunOthersapy Drugs for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Tonghua Dongbao Pharmaceutical
Sumitomo
Merck
Biogen
Schering-Plough
Roche
Glaxo
Chiron
Segment by Type
INF-α
IL-6
Rituximab
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ImmunOthersapy Drugs for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global ImmunOthersapy Drugs for Multiple Myeloma market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for ImmunOthersapy Drugs for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ImmunOthersapy Drugs for Multiple Myeloma.
Report Scope
The ImmunOthersapy Drugs for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ImmunOthersapy Drugs for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ImmunOthersapy Drugs for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Tonghua Dongbao Pharmaceutical
Sumitomo
Merck
Biogen
Schering-Plough
Roche
Glaxo
Chiron
Segment by Type
INF-α
IL-6
Rituximab
Others
Segment by Application
Hospital
Drug Center
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ImmunOthersapy Drugs for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 INF-α
1.2.3 IL-6
1.2.4 Rituximab
1.2.5 Others
1.3 Market by Application
1.3.1 Global ImmunOthersapy Drugs for Multiple Myeloma Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ImmunOthersapy Drugs for Multiple Myeloma Market Perspective (2019-2030)
2.2 ImmunOthersapy Drugs for Multiple Myeloma Growth Trends by Region
2.2.1 Global ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ImmunOthersapy Drugs for Multiple Myeloma Historic Market Size by Region (2019-2024)
2.2.3 ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Region (2025-2030)
2.3 ImmunOthersapy Drugs for Multiple Myeloma Market Dynamics
2.3.1 ImmunOthersapy Drugs for Multiple Myeloma Industry Trends
2.3.2 ImmunOthersapy Drugs for Multiple Myeloma Market Drivers
2.3.3 ImmunOthersapy Drugs for Multiple Myeloma Market Challenges
2.3.4 ImmunOthersapy Drugs for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ImmunOthersapy Drugs for Multiple Myeloma Players by Revenue
3.1.1 Global Top ImmunOthersapy Drugs for Multiple Myeloma Players by Revenue (2019-2024)
3.1.2 Global ImmunOthersapy Drugs for Multiple Myeloma Revenue Market Share by Players (2019-2024)
3.2 Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ImmunOthersapy Drugs for Multiple Myeloma Revenue
3.4 Global ImmunOthersapy Drugs for Multiple Myeloma Market Concentration Ratio
3.4.1 Global ImmunOthersapy Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ImmunOthersapy Drugs for Multiple Myeloma Revenue in 2023
3.5 ImmunOthersapy Drugs for Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players ImmunOthersapy Drugs for Multiple Myeloma Product Solution and Service
3.7 Date of Enter into ImmunOthersapy Drugs for Multiple Myeloma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ImmunOthersapy Drugs for Multiple Myeloma Breakdown Data by Type
4.1 Global ImmunOthersapy Drugs for Multiple Myeloma Historic Market Size by Type (2019-2024)
4.2 Global ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Type (2025-2030)
5 ImmunOthersapy Drugs for Multiple Myeloma Breakdown Data by Application
5.1 Global ImmunOthersapy Drugs for Multiple Myeloma Historic Market Size by Application (2019-2024)
5.2 Global ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America ImmunOthersapy Drugs for Multiple Myeloma Market Size (2019-2030)
6.2 North America ImmunOthersapy Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024)
6.4 North America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size (2019-2030)
7.2 Europe ImmunOthersapy Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024)
7.4 Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size (2019-2030)
8.2 Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (2019-2024)
8.4 Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size (2019-2030)
9.2 Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024)
9.4 Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size (2019-2030)
10.2 Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024)
10.4 Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Tonghua Dongbao Pharmaceutical
11.1.1 Tonghua Dongbao Pharmaceutical Company Detail
11.1.2 Tonghua Dongbao Pharmaceutical Business Overview
11.1.3 Tonghua Dongbao Pharmaceutical ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.1.4 Tonghua Dongbao Pharmaceutical Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.1.5 Tonghua Dongbao Pharmaceutical Recent Development
11.2 Sumitomo
11.2.1 Sumitomo Company Detail
11.2.2 Sumitomo Business Overview
11.2.3 Sumitomo ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.2.4 Sumitomo Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.2.5 Sumitomo Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.3.4 Merck Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.3.5 Merck Recent Development
11.4 Biogen
11.4.1 Biogen Company Detail
11.4.2 Biogen Business Overview
11.4.3 Biogen ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.4.4 Biogen Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.4.5 Biogen Recent Development
11.5 Schering-Plough
11.5.1 Schering-Plough Company Detail
11.5.2 Schering-Plough Business Overview
11.5.3 Schering-Plough ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.5.4 Schering-Plough Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.5.5 Schering-Plough Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.6.4 Roche Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Glaxo
11.7.1 Glaxo Company Detail
11.7.2 Glaxo Business Overview
11.7.3 Glaxo ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.7.4 Glaxo Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.7.5 Glaxo Recent Development
11.8 Chiron
11.8.1 Chiron Company Detail
11.8.2 Chiron Business Overview
11.8.3 Chiron ImmunOthersapy Drugs for Multiple Myeloma Introduction
11.8.4 Chiron Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
11.8.5 Chiron Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of INF-α
Table 3. Key Players of IL-6
Table 4. Key Players of Rituximab
Table 5. Key Players of Others
Table 6. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Region (2019-2024)
Table 10. Global ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Region (2025-2030)
Table 12. ImmunOthersapy Drugs for Multiple Myeloma Market Trends
Table 13. ImmunOthersapy Drugs for Multiple Myeloma Market Drivers
Table 14. ImmunOthersapy Drugs for Multiple Myeloma Market Challenges
Table 15. ImmunOthersapy Drugs for Multiple Myeloma Market Restraints
Table 16. Global ImmunOthersapy Drugs for Multiple Myeloma Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Players (2019-2024)
Table 18. Global Top ImmunOthersapy Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ImmunOthersapy Drugs for Multiple Myeloma as of 2023)
Table 19. Ranking of Global Top ImmunOthersapy Drugs for Multiple Myeloma Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by ImmunOthersapy Drugs for Multiple Myeloma Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players ImmunOthersapy Drugs for Multiple Myeloma Product Solution and Service
Table 23. Date of Enter into ImmunOthersapy Drugs for Multiple Myeloma Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global ImmunOthersapy Drugs for Multiple Myeloma Revenue Market Share by Type (2019-2024)
Table 27. Global ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global ImmunOthersapy Drugs for Multiple Myeloma Revenue Market Share by Type (2025-2030)
Table 29. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global ImmunOthersapy Drugs for Multiple Myeloma Revenue Market Share by Application (2019-2024)
Table 31. Global ImmunOthersapy Drugs for Multiple Myeloma Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global ImmunOthersapy Drugs for Multiple Myeloma Revenue Market Share by Application (2025-2030)
Table 33. North America ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size by Country (2025-2030) & (US$ Million)
Table 48. Tonghua Dongbao Pharmaceutical Company Detail
Table 49. Tonghua Dongbao Pharmaceutical Business Overview
Table 50. Tonghua Dongbao Pharmaceutical ImmunOthersapy Drugs for Multiple Myeloma Product
Table 51. Tonghua Dongbao Pharmaceutical Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 52. Tonghua Dongbao Pharmaceutical Recent Development
Table 53. Sumitomo Company Detail
Table 54. Sumitomo Business Overview
Table 55. Sumitomo ImmunOthersapy Drugs for Multiple Myeloma Product
Table 56. Sumitomo Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 57. Sumitomo Recent Development
Table 58. Merck Company Detail
Table 59. Merck Business Overview
Table 60. Merck ImmunOthersapy Drugs for Multiple Myeloma Product
Table 61. Merck Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 62. Merck Recent Development
Table 63. Biogen Company Detail
Table 64. Biogen Business Overview
Table 65. Biogen ImmunOthersapy Drugs for Multiple Myeloma Product
Table 66. Biogen Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 67. Biogen Recent Development
Table 68. Schering-Plough Company Detail
Table 69. Schering-Plough Business Overview
Table 70. Schering-Plough ImmunOthersapy Drugs for Multiple Myeloma Product
Table 71. Schering-Plough Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 72. Schering-Plough Recent Development
Table 73. Roche Company Detail
Table 74. Roche Business Overview
Table 75. Roche ImmunOthersapy Drugs for Multiple Myeloma Product
Table 76. Roche Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 77. Roche Recent Development
Table 78. Glaxo Company Detail
Table 79. Glaxo Business Overview
Table 80. Glaxo ImmunOthersapy Drugs for Multiple Myeloma Product
Table 81. Glaxo Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 82. Glaxo Recent Development
Table 83. Chiron Company Detail
Table 84. Chiron Business Overview
Table 85. Chiron ImmunOthersapy Drugs for Multiple Myeloma Product
Table 86. Chiron Revenue in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024) & (US$ Million)
Table 87. Chiron Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Type: 2023 VS 2030
Figure 3. INF-α Features
Figure 4. IL-6 Features
Figure 5. Rituximab Features
Figure 6. Others Features
Figure 7. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Application: 2023 VS 2030
Figure 9. Hospital Case Studies
Figure 10. Drug Center Case Studies
Figure 11. Clinic Case Studies
Figure 12. Others Case Studies
Figure 13. ImmunOthersapy Drugs for Multiple Myeloma Report Years Considered
Figure 14. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global ImmunOthersapy Drugs for Multiple Myeloma Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Region: 2023 VS 2030
Figure 17. Global ImmunOthersapy Drugs for Multiple Myeloma Market Share by Players in 2023
Figure 18. Global Top ImmunOthersapy Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in ImmunOthersapy Drugs for Multiple Myeloma as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by ImmunOthersapy Drugs for Multiple Myeloma Revenue in 2023
Figure 20. North America ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America ImmunOthersapy Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 22. United States ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe ImmunOthersapy Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 26. Germany ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific ImmunOthersapy Drugs for Multiple Myeloma Market Share by Region (2019-2030)
Figure 34. China ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America ImmunOthersapy Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 42. Mexico ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa ImmunOthersapy Drugs for Multiple Myeloma Market Share by Country (2019-2030)
Figure 46. Turkey ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia ImmunOthersapy Drugs for Multiple Myeloma Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Tonghua Dongbao Pharmaceutical Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 49. Sumitomo Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 50. Merck Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 51. Biogen Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 52. Schering-Plough Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 53. Roche Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 54. Glaxo Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 55. Chiron Revenue Growth Rate in ImmunOthersapy Drugs for Multiple Myeloma Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
